These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6811538)

  • 1. Pharmacological studies on carbapenem antibiotics. I. Metabolism of PS-5 in animal tissues.
    Shibamoto N; Sakamoto M; Iguchi H; Tone H; Fukagawa Y; Ishikura T
    J Antibiot (Tokyo); 1982 Jun; 35(6):721-8. PubMed ID: 6811538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological studies on carbapenem antibiotics. II. Isolation of a PS-5-inactivating factor from the rat kidney.
    Shibamoto N; Sakamoto M; Fukagawa Y; Ishikura T
    J Antibiot (Tokyo); 1982 Jun; 35(6):729-35. PubMed ID: 6811539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the OA-6129 group of antibiotics, new carbapenem compounds. II. In vitro evaluation.
    Sakamoto M; Kojima I; Okabe M; Fukagawa Y; Ishikura T
    J Antibiot (Tokyo); 1982 Oct; 35(10):1264-70. PubMed ID: 7174514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological studies on carbapenem antibiotics. III. Chemical structure of PS-5D III, the primary renal metabolite of PS-5.
    Shibamoto N; Yoshioka T; Sakamoto M; Fukagawa Y; Ishikura T
    J Antibiot (Tokyo); 1982 Jun; 35(6):736-41. PubMed ID: 6981638
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.
    Kropp H; Sundelof JG; Hajdu R; Kahan FM
    Antimicrob Agents Chemother; 1982 Jul; 22(1):62-70. PubMed ID: 7125632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.
    Norrby SR; Alestig K; Ferber F; Huber JL; Jones KH; Kahan FM; Meisinger MA; Rogers JD
    Antimicrob Agents Chemother; 1983 Feb; 23(2):293-9. PubMed ID: 6573156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of MM 13902 and other carbapenem antibiotics in vitro and in vivo.
    Basker MJ; Boon RJ; Box SJ; Prestige EA; Smith GM; Spear SR
    J Antibiot (Tokyo); 1983 Apr; 36(4):416-22. PubMed ID: 6406413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [N-Formimidoyl-thienamycin in Animal Studies].
    Ritzerfeld W
    Arzneimittelforschung; 1983; 33(3):470-2. PubMed ID: 6575782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of N-formimidoyl thienamycin and influence of a renal dipeptidase inhibitor in experimental meningitis.
    Washburn DE; Perfect JR; Durack DT
    J Antimicrob Chemother; 1983 Jul; 12(1):39-45. PubMed ID: 6578210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
    Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K
    Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PS-6 and PS-7, new beta-lactam antibiotics. In vitro and in vivo evaluation.
    Sakamoto M; Shibamoto N; Iguchi H; Okamura K; Hori S; Fukagawa Y; Ishikura T; Lein J
    J Antibiot (Tokyo); 1980 Oct; 33(10):1138-45. PubMed ID: 7451364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the biosynthesis of carbapenem antibiotics. I. Biosynthetic significance of the OA-6129 group of carbapenem compounds as the direct precursors for PS-5, epithienamycins A and C and MM 17880.
    Fukagawa Y; Okabe M; Azuma S; Kojima I; Ishikura T; Kubo K
    J Antibiot (Tokyo); 1984 Nov; 37(11):1388-93. PubMed ID: 6511666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deacetylation of PS-5, a new beta-lactam compound, I. Microbial deacetylation of PS-5.
    Fukagawa Y; Kubo K; Ishikura T; Kouno K
    J Antibiot (Tokyo); 1980 Jun; 33(6):543-9. PubMed ID: 6897941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of dehydropeptidase-I and comparative in vitro and in vivo stabilities of PS-5 derivatives modified at the C-3 side chain.
    Sakamoto M; Yamamoto K; Isshiki K; Tone H; Ishikura T; Fukagawa Y; Yoshioka T
    Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):341-8. PubMed ID: 2054858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
    Moon YS; Chung KC; Gill MA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition and metabolism of meropenem in laboratory animals and man.
    Harrison MP; Moss SR; Featherstone A; Fowkes AG; Sanders AM; Case DE
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():265-77. PubMed ID: 2808212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of human pharmacokinetics of panipenem, a new carbapenem antibiotic, from animal data.
    Nakashima M; Kurihara A; Hisaoka M
    Drugs Exp Clin Res; 1992; 18(9):371-5. PubMed ID: 1299587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the renal excretory mechanisms of cefmenoxime and other cephalosporins: renal clearance in rats and rabbits.
    Yamazaki I; Shirakawa Y; Fugono T
    J Antibiot (Tokyo); 1981 Aug; 34(8):1055-63. PubMed ID: 6274837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.